Masimo (NASDAQ:MASI - Get Free Report) had its price target upped by Piper Sandler from $117.00 to $126.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has a "neutral" rating on the medical equipment provider's stock. Piper Sandler's target price would suggest a potential upside of 4.98% from the company's current price.
A number of other brokerages have also recently weighed in on MASI. BTIG Research increased their price target on Masimo from $145.00 to $166.00 and gave the stock a "buy" rating in a research report on Monday, March 25th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Wednesday. Wells Fargo & Company raised shares of Masimo from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $117.00 to $160.00 in a report on Monday, March 25th. Stifel Nicolaus raised shares of Masimo from a "hold" rating to a "buy" rating and boosted their target price for the company from $148.00 to $170.00 in a research note on Monday, April 15th. Finally, StockNews.com upgraded shares of Masimo from a "sell" rating to a "hold" rating in a research note on Friday, March 29th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $138.71.
Get Our Latest Report on MASI
Masimo Stock Down 11.8 %
Shares of NASDAQ MASI traded down $15.98 during trading on Wednesday, reaching $120.02. 2,332,545 shares of the stock were exchanged, compared to its average volume of 581,284. The business's 50-day moving average price is $136.36 and its 200 day moving average price is $119.58. The company has a market capitalization of $6.35 billion, a price-to-earnings ratio of 79.63 and a beta of 0.99. Masimo has a twelve month low of $75.22 and a twelve month high of $188.14. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64.
Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The medical equipment provider reported $0.77 EPS for the quarter, beating the consensus estimate of $0.71 by $0.06. The business had revenue of $492.80 million during the quarter, compared to analyst estimates of $487.70 million. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The company's quarterly revenue was down 12.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.87 EPS. As a group, equities analysts forecast that Masimo will post 3.51 EPS for the current fiscal year.
Insider Activity at Masimo
In other Masimo news, Director Craig B. Reynolds sold 40,000 shares of the company's stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $136.17, for a total value of $5,446,800.00. Following the completion of the sale, the director now directly owns 7,406 shares in the company, valued at $1,008,475.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 9.70% of the company's stock.
Institutional Investors Weigh In On Masimo
A number of institutional investors and hedge funds have recently bought and sold shares of MASI. Riverview Trust Co acquired a new stake in Masimo during the first quarter valued at approximately $25,000. Massmutual Trust Co. FSB ADV increased its holdings in shares of Masimo by 140.6% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider's stock valued at $28,000 after buying an additional 142 shares in the last quarter. Byrne Asset Management LLC acquired a new position in shares of Masimo in the 4th quarter worth $28,000. NBC Securities Inc. acquired a new stake in shares of Masimo during the third quarter worth $34,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of Masimo by 851.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 264 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.
Masimo Company Profile
(
Get Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
Featured Articles
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
